Aker BioMarine announced a publication of its first preclinical study on krill powder and the effect of krill powder supplementation on the disturbed lipid metabolism and inflammation in a mouse model of chronic inflammation in the journal Metabolism: Clinical and Experimental.
Researchers from University of Bergen, Norway performed the study, in which they investigated the effect of feeding mice a high-fat diet with or without krill powder for six weeks. Chronic low-grade inflammation is linked to obesity and the metabolic syndrome by unfavorably affecting lipid metabolism. Superba Krill powder extracted from Antarctic krill (Euphausia superba) contains approximately 40 percent protein and 60 percent lipid of which 34 percent of the fatty acids are omega-3 fatty acids.
The study results showed that feeding krill powder in addition to a high-fat diet to mice with persistent inflammation increased degradation of fatty acids, reduced the generation of fat and lowered the expression of genes involved in cholesterol and glucose metabolism that resulted in improved blood and liver lipid levels. Moreover, inflammatory markers in the liver were significantly reduced.
According to study author Lena Burri, PhD, "These findings support further clinical studies to investigate if krill powder also has lipid-lowering and anti-inflammatory effects in humans and could alleviate obesity-related disorders."
Matts Johansen, executive vice president of sales and marketing at Aker BioMarine, confirms that a commercial launch of the phospholipid-rich Superba krill powder is right around the corner, and that a clinical study on inflammation and joint health with Superba krill powder is planned for this year.
The Superba krill powder is unique and produced onboard our MSC-certfied vessel Saga Sea with a patent-pending technology. It provides customers with the possibility to formulate the fast-growing krill ingredient into tablets and other dry forms.